S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study
Phase 2
Completed
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: S1 combined with cisplatin
- Registration Number
- NCT01854749
- Lead Sponsor
- Fudan University
- Brief Summary
Assess the efficacy and safety of S1 combined with cisplatin in treatment of recurrence/metastasis of ESCC
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 57
Inclusion Criteria
Not provided
Exclusion Criteria
-
there is radical cure of the cancer
- uncontrolled chronic diarrhea and esophageal obstruction
- Neurological or mental abnormalities Influence of cognitive ability include central nervous system metastases
- Severe complication(s), e.g.,uncontrolled active infection,myocardial infarction,hypertension,arrhythmia,stenocardia
- Patient who has metastasis except cured skin basal cell carcinoma and carcinoma in situ of cervix
-
accept other antitumor therapy •Female patients during their pregnant and lactation period, or patients without contraception
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description S1 combined with cisplatin S1 combined with cisplatin -
- Primary Outcome Measures
Name Time Method Progression Free Survival from the first cycle of treatment (day one) to two month after the last cycle
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Cancer hospital Fudan University
🇨🇳Shanghai, Shanghai, China